BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation
BERGEN, Norway, May 13, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020. A webcast presentation by BerGenBio's senior management team will take place at 10 am CET.
The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.
The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
For more information, please contact:
CEO, BerGenBio ASA
CFO, BerGenBio ASA
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs,
Consilium Strategic Communications
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
For more information, visit www.bergenbio.com
This information was brought to you by Cision http://news.cision.com
SOURCE BerGenBio ASA